WO2012026712A3 - Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 - Google Patents

Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 Download PDF

Info

Publication number
WO2012026712A3
WO2012026712A3 PCT/KR2011/006109 KR2011006109W WO2012026712A3 WO 2012026712 A3 WO2012026712 A3 WO 2012026712A3 KR 2011006109 W KR2011006109 W KR 2011006109W WO 2012026712 A3 WO2012026712 A3 WO 2012026712A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
nod2
cultured product
pharmaceutical composition
diseases
Prior art date
Application number
PCT/KR2011/006109
Other languages
English (en)
French (fr)
Other versions
WO2012026712A4 (ko
WO2012026712A2 (ko
Inventor
강경선
김형식
Original Assignee
주식회사 강스템홀딩스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 강스템홀딩스 filed Critical 주식회사 강스템홀딩스
Priority to US13/818,234 priority Critical patent/US9408873B2/en
Priority to EP11820139.1A priority patent/EP2620156B1/en
Priority to PL11820139T priority patent/PL2620156T3/pl
Priority to CN201610098546.4A priority patent/CN105727250B/zh
Priority to ES11820139T priority patent/ES2727030T3/es
Priority to CN201180045953.4A priority patent/CN103118691B/zh
Priority to JP2013525815A priority patent/JP5805195B2/ja
Publication of WO2012026712A2 publication Critical patent/WO2012026712A2/ko
Publication of WO2012026712A3 publication Critical patent/WO2012026712A3/ko
Publication of WO2012026712A4 publication Critical patent/WO2012026712A4/ko
Priority to US15/231,223 priority patent/US20170007668A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/054—Muramyle peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)

Abstract

본 발명은 NOD2를 발현하는 줄기세포에 NOD2의 아고니스트를 첨가하여 배양한 줄기세포 또는 그 배양물을 포함하는 면역질환 및 염증질환의 예방 또는 치료용 약학조성물에 관한 것으로, 보다 상세하게는 상기 약학조성물, 상기 상기 줄기세포 또는 그 배양물을 피험체에 투여하는 단계를 포함하는 피험체의 면역반응 또는 염증반응을 억제하는 방법, 상기 줄기세포 또는 그 배양물을 이용하여 면역억제제 또는 항염증제의 제조 방법, NOD2를 발현하는 줄기세포에 NOD2의 아고니스트를 첨가하여 배양하는 단계를 포함하는 PGE2 또는 TGF-β1의 제조 방법, NOD2를 발현하는 줄기세포 및 NOD2의 아고니스트를 포함하는 이식체, 상기 이식체의 제조방법, NOD2를 발현하는 줄기세포 및 NOD2의 아고니스트를 포함하는 복합체 및 NOD2를 발현하는 줄기세포에 NOD2의 아고니스트를 첨가하여 얻은 배양물에 관한 것이다.
PCT/KR2011/006109 2010-08-23 2011-08-19 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 WO2012026712A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US13/818,234 US9408873B2 (en) 2010-08-23 2011-08-19 Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
EP11820139.1A EP2620156B1 (en) 2010-08-23 2011-08-19 Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
PL11820139T PL2620156T3 (pl) 2010-08-23 2011-08-19 Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób immunologicznych lub chorób zapalnych, zawierająca komórki macierzyste traktowane agonistą NOD2 lub jego produktem hodowlanym
CN201610098546.4A CN105727250B (zh) 2010-08-23 2011-08-19 预防和治疗免疫病变和炎性疾病的药物组合物
ES11820139T ES2727030T3 (es) 2010-08-23 2011-08-19 Composición farmacéutica para prevenir o tratar enfermedades inmunitarias o enfermedades inflamatorias, que contiene células madre tratadas con agonista de NOD2 o un producto cultivado del mismo
CN201180045953.4A CN103118691B (zh) 2010-08-23 2011-08-19 预防和治疗免疫病变和炎性疾病的包括用nod2激动剂处理的干细胞或其培养物的药物组合物
JP2013525815A JP5805195B2 (ja) 2010-08-23 2011-08-19 Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
US15/231,223 US20170007668A1 (en) 2010-08-23 2016-08-08 Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0081640 2010-08-23
KR20100081640 2010-08-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/818,234 A-371-Of-International US9408873B2 (en) 2010-08-23 2011-08-19 Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
US15/231,223 Continuation-In-Part US20170007668A1 (en) 2010-08-23 2016-08-08 Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases

Publications (3)

Publication Number Publication Date
WO2012026712A2 WO2012026712A2 (ko) 2012-03-01
WO2012026712A3 true WO2012026712A3 (ko) 2012-05-24
WO2012026712A4 WO2012026712A4 (ko) 2012-08-23

Family

ID=45723902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006109 WO2012026712A2 (ko) 2010-08-23 2011-08-19 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물

Country Status (8)

Country Link
US (1) US9408873B2 (ko)
EP (1) EP2620156B1 (ko)
JP (1) JP5805195B2 (ko)
KR (4) KR101480362B1 (ko)
CN (2) CN103118691B (ko)
ES (1) ES2727030T3 (ko)
PL (1) PL2620156T3 (ko)
WO (1) WO2012026712A2 (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013125899A1 (ko) * 2012-02-22 2013-08-29 주식회사 강스템홀딩스 줄기세포를 유효 성분으로 함유하는 면역 질환 또는 염증 질환의 예방 또는 치료용 조성물
CA2876499C (en) * 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
EP2716298A1 (en) * 2012-10-03 2014-04-09 Institut Pasteur A nod2-dependant pathway of cytoprotection of stem cells
US9498498B2 (en) * 2013-03-15 2016-11-22 Avita International Ltd. Adipose tissue mesenchymal stem cells and methods of use to treat or inhibit uterine disorders
KR102084974B1 (ko) 2013-07-30 2020-03-06 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
JP6769970B2 (ja) * 2015-01-12 2020-10-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 免疫媒介性疾患の防止及び処置におけるムラミルペプチドに対するモノクローナル抗体
JP7057557B2 (ja) * 2015-07-31 2022-04-20 国立大学法人大阪大学 上皮疾患に対する治療及び／又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
RS64469B1 (sr) * 2015-07-31 2023-09-29 Exotropin Llc Kompozicije egzozoma i postupci za njihovu pripremu i primenu za regulisanje i kondicioniranje kože i kose
CR20180184A (es) * 2015-08-31 2018-08-23 Dong A Socio Holdings Co Ltd Compuestos heteroarilo y su uso como fármacos terapéuticos
WO2017171491A1 (ko) * 2016-03-31 2017-10-05 재단법인 아산사회복지재단 줄기세포 추출물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물
EP3523292B1 (en) 2016-10-10 2021-12-15 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as mer inhibitors
JP7168653B2 (ja) * 2017-08-16 2022-11-09 スンクワン メディカル ファウンデーション 間葉系幹細胞を含む甲状腺眼症を治療するための組成物
EP3713548A4 (en) * 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGICAL COMPOSITIONS
CN110090228A (zh) * 2018-04-18 2019-08-06 浙江大学 人羊膜上皮细胞在自身免疫性疾病中的治疗用途
JP6497827B1 (ja) * 2018-07-17 2019-04-10 株式会社 バイオミメティクスシンパシーズ エイコサノイド産生促進剤
CN110075269B (zh) * 2019-04-19 2021-06-29 中国人民解放军第二军医大学 Murabutide在制备电离辐射致骨髓、小肠和脾脏损伤防治药物中应用
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
AU2020383510A1 (en) * 2019-11-12 2022-05-12 Orchard Therapeutics (Europe) Limited Compositions and methods for treating or preventing Crohn's disease
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
CN113827618B (zh) * 2021-10-20 2023-09-26 上海交通大学医学院附属仁济医院 干细胞条件培养基在制备用于治疗炎症性皮肤的药物中的用途
WO2024084448A2 (en) * 2022-10-20 2024-04-25 Dong-A St Co., Ltd. Fused bicyclic compounds and their use as mer and axl inhibitors
CN116077530A (zh) * 2022-11-21 2023-05-09 中南大学 预处理的人羊膜上皮细胞在制备治疗和/或预防炎症疾病药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070564A1 (en) * 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
US20090169522A1 (en) * 2006-01-13 2009-07-02 Alla Danilkovitch Mesenchymal stem cells expressing tnf-a receptor
US20090202479A1 (en) * 2008-01-31 2009-08-13 Yufang Shi Method for modulating immune responses using stem cells and cytokines
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
KR960033469U (ko) 1995-04-24 1996-11-19 배인식 보온 급식통
AU2004286002B2 (en) 2003-10-31 2011-01-27 The University Of British Columbia Bacterial virulence factors and uses thereof
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
US20060251659A1 (en) * 2005-04-13 2006-11-09 Stephen Girardin Method for screening molecules that restore NOD1 activity in cells containing an NOD2 mutation that reduces or eliminates NOD1 activity
WO2006109300A1 (en) * 2005-04-14 2006-10-19 Hadasit Medical Research Services & Development Ltd. Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
GB0603427D0 (en) * 2006-02-21 2006-04-05 Ucl Biomedica Plc IL-8 Therapy
US20100226976A1 (en) * 2007-07-11 2010-09-09 Marcelle Machluf Encapsulated mesenchymal stem cells and uses thereof
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
WO2009129616A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169522A1 (en) * 2006-01-13 2009-07-02 Alla Danilkovitch Mesenchymal stem cells expressing tnf-a receptor
WO2008070564A1 (en) * 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
US20090202479A1 (en) * 2008-01-31 2009-08-13 Yufang Shi Method for modulating immune responses using stem cells and cytokines
WO2009114860A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORZUTZKY A. ET AL.: "NOD2-associated diseases: Bridging innate immunity and autoinflammation", CLINICAL IMMUNOLOGY, vol. 134, March 2010 (2010-03-01), pages 251 - 261, XP055081056 *

Also Published As

Publication number Publication date
EP2620156A2 (en) 2013-07-31
US9408873B2 (en) 2016-08-09
WO2012026712A4 (ko) 2012-08-23
KR20140019461A (ko) 2014-02-14
KR101480362B1 (ko) 2015-01-28
KR20170091064A (ko) 2017-08-08
CN103118691B (zh) 2016-08-24
KR20190089812A (ko) 2019-07-31
CN105727250B (zh) 2023-11-07
JP5805195B2 (ja) 2015-11-04
CN105727250A (zh) 2016-07-06
ES2727030T3 (es) 2019-10-11
US20130209422A1 (en) 2013-08-15
KR20120018724A (ko) 2012-03-05
WO2012026712A2 (ko) 2012-03-01
CN103118691A (zh) 2013-05-22
PL2620156T3 (pl) 2019-10-31
EP2620156A4 (en) 2014-08-20
EP2620156B1 (en) 2019-03-27
JP2013536222A (ja) 2013-09-19

Similar Documents

Publication Publication Date Title
WO2012026712A3 (ko) Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
AU2018256579A1 (en) Methods for preparing a skin graft
MY187874A (en) Antibody formulations
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MY175979A (en) Certain chemical entities, compositions and methods
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2009137674A3 (en) Treating myelin diseases with optimized cell preparations
WO2011130402A3 (en) Hepatocyte production by forward programming
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
WO2012006440A3 (en) Endothelial cell production by programming
WO2013010090A3 (en) Algal lipid compositions and methods of preparing and utilizing the same
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2012140127A3 (en) Method for priming of t cells
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
EP3030647A4 (en) Methods of producing algal cell cultures and biomass, lipid compounds and compositions, and related products
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
WO2012097091A3 (en) Engineered microorganisms with enhanced fermentation activity
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
SG178593A1 (en) Use of lanostanes and extracts from poria cocos for treating diabetes
WO2012017322A3 (en) Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein
AU2010286532A8 (en) Methods of treatment using anti-oxidized LDL antibodies
WO2013162905A8 (en) Methods of producing and using regulatory b-cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180045953.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820139

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013525815

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011820139

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13818234

Country of ref document: US